115 related articles for article (PubMed ID: 23509198)
1. CA 19-9 concentration in peripheral and portal blood of patients operated on for pancreatic tumor.
Szwedziak K; Strzelczyk J
Pol Przegl Chir; 2013 Jan; 85(1):20-8. PubMed ID: 23509198
[TBL] [Abstract][Full Text] [Related]
2. CA 125 concentration in portal blood as a predictor of resectability in pancreatic tumor.
Szwedziak K; Szymański D; Strzelczyk J
Contemp Oncol (Pozn); 2013; 17(4):394-9. PubMed ID: 24592129
[TBL] [Abstract][Full Text] [Related]
3. [The technique of radical pancreaticoduodenectomy for malignant tumor in pancreatic head with pressed superior mesenteric blood vessels or portal vein].
Qin RY; Zou SQ; Qiu FZ
Zhonghua Wai Ke Za Zhi; 2008 Mar; 46(5):366-9. PubMed ID: 18785534
[TBL] [Abstract][Full Text] [Related]
4. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions.
Cwik G; Wallner G; Skoczylas T; Ciechanski A; Zinkiewicz K
Arch Surg; 2006 Oct; 141(10):968-73; discussion 974. PubMed ID: 17043274
[TBL] [Abstract][Full Text] [Related]
5. Thyroid hormones concentration in portal and peripheral blood in patients with pancreatic cancer: Preliminary study.
Strzałka A; Hogendorf P; Skulimowski A; Spychalski M; Strzelczyk J; Durczynski A
Cancer Biomark; 2020; 29(3):301-306. PubMed ID: 32568183
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic mucinous cystadenoma with serum CA 19-9 over 1,000,000 U/mL: a case report and review of the literature.
Costa WL; Mantoan H; Brito RH; Ribeiro HS; Diniz AL; Godoy AL; Farias IC; Begnami MD; Soares FA; Coimbra FJ
World J Surg Oncol; 2015 Feb; 13():78. PubMed ID: 25888888
[TBL] [Abstract][Full Text] [Related]
7. Elevated tumor marker CA 19-9 in the differential diagnosis of pancreatic mass lesions.
Cwik G; Wallner G; Skoczylas T; Krzyzanowski M; Ciechainski A; Madro P
Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):213-8. PubMed ID: 16146081
[TBL] [Abstract][Full Text] [Related]
8. Very high concentration of D-dimers in portal blood in patients with pancreatic cancer.
Durczyński A; Szymański D; Nowicki M; Hogendorf P; Poznańska G; Strzelczyk J
Pol Przegl Chir; 2012 Oct; 84(10):521-5. PubMed ID: 23324368
[TBL] [Abstract][Full Text] [Related]
9. Preoperative Platelet-Lymphocyte Ratio Augments CA 19-9 as a Predictor of Malignancy in Chronic Calcific Pancreatitis.
Rammohan A; Cherukuri SD; Palaniappan R; Perumal SK; Sathyanesan J; Govindan M
World J Surg; 2015 Sep; 39(9):2323-8. PubMed ID: 25917199
[TBL] [Abstract][Full Text] [Related]
10. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors].
Markocka-Maczka K
Wiad Lek; 2003; 56(11-12):537-40. PubMed ID: 15058160
[TBL] [Abstract][Full Text] [Related]
11. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
12. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
13. [Differential diagnosis of pancreatic head cancer].
Kubyshkin VA; Vishnevskiĭ VA; Aĭrapetian AT; Karmazanovskiĭ GG; Kuntsevich GI; Starkov IuG
Khirurgiia (Mosk); 2000; (11):19-23. PubMed ID: 11220911
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms.
Safi F; Schlosser W; Kolb G; Beger HG
J Gastrointest Surg; 1997; 1(2):106-12. PubMed ID: 9834336
[TBL] [Abstract][Full Text] [Related]
15. Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis.
Nishida K; Kaneko T; Yoneda M; Nakagawa S; Ishikawa T; Yamane E; Nishioka B; Miyamoto Y; Takano H; Yoshikawa T; Kondo M
J Surg Oncol; 1999 Jul; 71(3):140-6. PubMed ID: 10404129
[TBL] [Abstract][Full Text] [Related]
16. Clinical presentation and comparison of surgical outcome for segmental resection vs. Whipple's procedure for solid pseudopapillary tumor: Report of six new cases & literature review of 321 cases.
Manuballa V; Amin M; Cappell MS
Pancreatology; 2014; 14(1):71-80. PubMed ID: 24555981
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E2 (PGE2) in portal blood in patients with pancreatic tumor--a single institution series.
Hogendorf P; Durczyński A; Kumor A; Strzelczyk J
J Invest Surg; 2012 Feb; 25(1):8-13. PubMed ID: 22272632
[TBL] [Abstract][Full Text] [Related]
19. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
20. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
